Di’ao Xinxuekang Capsule Improves the Anti-Atherosclerotic Effect of Atorvastatin by Downregulating the SREBP2/PCSK9 Signalling Pathway

Statins are the first choice for lowering low-density lipoprotein cholesterol (LDL-C) and preventing atherosclerotic cardiovascular disease (ASCVD). However, statins can also upregulate proprotein convertase subtilisin/kexin type 9 (PCSK9), which in turn might limits the cholesterol-lowering effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Jiyi, Li, Wei, Liu, Honglin, Li, Xiaofen, Yuan, Chuqiao, Zou, Wenjun, Qu, Liping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096164/
https://www.ncbi.nlm.nih.gov/pubmed/35571088
http://dx.doi.org/10.3389/fphar.2022.857092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096164/
https://www.ncbi.nlm.nih.gov/pubmed/35571088
http://dx.doi.org/10.3389/fphar.2022.857092

Ejemplares similares